- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07577388
Bed Rest With a Short Cervix on Preterm Birth (BEWISE)
BEWISE - Bed Rest With a Short Cervix on Preterm Birth
Maternal AR has long been used to prevent PTB. However, definitions of AR vary widely, ranging from complete bed rest to partial limitation of physical activity for one or more hours daily.
The use of maternal AR to prevent preterm birth is largely based on observational evidence linking strenuous physical activity to an increased risk of preterm birth, and the assumption that reduced activity may decrease myometrial activity. However, the existing evidence on the clinical effects of AR remains limited and has not demonstrated a reduction in preterm birth or a delay in deliv-ery. In contrast, some studies suggest a potential increase in preterm birth following AR and instead significant adverse maternal and fetal effects.
The overall aim of this study is to compare gestational age at birth in women with a short cervix who are prescribed AR compared with women with a short cervix who are not prescribed AR (NAR).
The primary hypothesis is that NAR is non-inferior to AR in prolonging pregnancy in women with a short cervix.
Secondary hypotheses are that, compared with AR, NAR is associated with higher level of physical activity, lower risk of maternal depression, and reduced risk of loss of maternal bone mineral density.
Through the BEWISE study, we wish to implement a change in the Danish national clinical practice regarding AR from recommending AR in risk groups (current practice) to no longer recommending AR as part as routine care (new practice). We will evaluate this change in clinical practice by prospectively collecting data from women both before and after implementation of the new recommendation. The transition from AR to NAR will be implemented sequentially in each Danish region using a randomised stepped-wedge (SW) cluster design, with each region constituting a cluster. The order in which regions transition is determined by randomisation. Each region will adopt the new recommendation at 3-month intervals, resulting in full national transition from AR to NAR within 12 months Eligible participants are pregnant women in gestational age 20+0 to 33+6 and cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies. Participants must be above 18 years of age and be able to read and understand Danish or English. There are no exclusion criteria.
The primary outcome is gestational age in days (continuous).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Kirsten Bünemann, Medical Doctor, PhD-student
- Telefonnummer: +45 40329849
- E-mail: kirsten.bunemann@clin.au.dk
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Pregnant women with gestational age 20+0 to 33+6
- Cervical length < 25 mm in singleton pregnancies and < 30 mm in multiple pregnancies
- Above 18 years of age
- Reads and understands Danish or English
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Activity Restriction
The comparison arm reflects current Danish clinical practice in each participating region.
According to national recommendations, AR is indicated before GA 28+0, with the level of restriction determined by cervical length and clinical context.
In singleton pregnancies with a cervix <10 mm in singleton/<15 mm in twins, strict AR is prescribed, defined as bed rest with only toilet allowance.
In addition, thrombosis prophylaxis (Low Molecular Weight Heparin and compression stockings) is initiated in cases of strict AR.
In women with a cervix of 10-14 mm in singletons/15-20 mm in twins, or in cases of PPROM with a cervix <25 mm, moderate AR is prescribed, defined as 2-8 hours of daily bed rest.
The regimen is continued until 28 weeks of gestation.
|
Recommendation to restrict physical activity in pregnant women with a short cervix.
This may include increased rest or bed rest according to local clinical practice.
Andre navne:
|
|
Eksperimentel: No Activity Restriction
The intervention consists of a recommendation of NAR during pregnancy. No general or graded restrictions on daily activities are advised, and cervical length is not an indication for activity limitation, in line with current evidence. The NAR recommendation is supported by a pragmatic clinical guidance. Women are advised to avoid activities that provoke pain, increase uterine contractions, or worsen pelvic pressure. Decisions regarding hospital admission or sick leave are based on individual clinical assessment rather than cervical length. Specific advice may be provided when clinically indicated. Women are generally advised to avoid heavy weight-bearing exercise and lifting of objects exceeding approximately 10 kg. Otherwise, no specific restrictions on physical activity are imposed, provided that activities do not provoke symptoms such as pain, increased uterine contractions, or pelvic pressure. Sexual activity may be ad-dressed on an individual basis following clinical assessment. |
Recommendation to continue normal daily activity in pregnant women with a short cervix, without restricting physical activity.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Gestational age at birth
Tidsramme: At birth (from inclusion until delivery)
|
Gestational age at birth measured in completed days of pregnancy.
This is calculated based on the estimated due date from ultrasound (crown-rump lenght <14weeks).
|
At birth (from inclusion until delivery)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Birth before 37 weeks of gestation
Tidsramme: At birth
|
At birth
|
|
|
Gestational age at birth, pooled
Tidsramme: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Latency from inclusion to birth (days)
Tidsramme: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Onset of birth
Tidsramme: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Mode of birth
Tidsramme: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
- Non-occipital presentation
Tidsramme: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Interventions during birth
Tidsramme: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Degree of birth tear
Tidsramme: At birth (from inclusion until delivery)
|
|
At birth (from inclusion until delivery)
|
|
Maternal serious morbidity
Tidsramme: From inclusion to 42 days after delivery
|
Admission to an intensive care unit or a unit providing 24-hour medical supervision, mechanical ventilation, or continuous vasoactive drug support at any time during pregnancy and postpartum due to pregnancy- or childbirth-related complications
|
From inclusion to 42 days after delivery
|
|
Umbilical cord arterial pH
Tidsramme: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
EPDS depression score
Tidsramme: From inclusion to 8 weeks after due date
|
From inclusion to 8 weeks after due date
|
|
|
Bone turnover marker level
Tidsramme: At inclusion and after 4 and 8 weeks.
|
|
At inclusion and after 4 and 8 weeks.
|
|
Lumbar spine Z-score
Tidsramme: 12 months after stopped breastfeeding
|
12 months after stopped breastfeeding
|
|
|
Data from SENS activity tracker
Tidsramme: At birth (from inclusion until delivery)
|
Step count Time in supine position
|
At birth (from inclusion until delivery)
|
|
Neonatal mortality
Tidsramme: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Fetal loss
Tidsramme: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Birth weight
Tidsramme: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
|
|
Neonatal admission, days
Tidsramme: From inclusion until discharge or 44 postmenstrual weeks
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
|
CNS morbidity
Tidsramme: From inclusion until discharge or 44 postmenstrual weeks
|
Intraventricular haemorrhage grade III or IV, Periventricular leukomalacia
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
Gastrointestinal morbidity
Tidsramme: From inclusion until discharge or 44 postmenstrual weeks
|
Necrotizing enterocolitis (NEC) requiring surgery (Bell's stage 3), Spontaneous intestinal perfo-ration (SIP) requiring surgical treatment
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
Respiratory support
Tidsramme: From inclusion until discharge or 44 postmenstrual weeks
|
Mechanical ventilation or non-invasive ventilation (NIV)
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
Respiratory distress syndrome (RDS)
Tidsramme: From inclusion until discharge or 44 postmenstrual weeks
|
From inclusion until discharge or 44 postmenstrual weeks
|
|
|
Early onset infection
Tidsramme: From inclusion to 5 days after birth
|
Definition: >5 days of i.v.
antibiotics where the treatment starts within the first week after delivery.
|
From inclusion to 5 days after birth
|
|
Apgar score at 5 minutes
Tidsramme: At birth (from inclusion until delivery)
|
At birth (from inclusion until delivery)
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Julie Glavind, Senior Consultant, MD, PhD, Aarhus Univeristy Hospital, Department of Obstetrics and Gynecology
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Psykiske lidelser
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Obstetriske arbejdskomplikationer
- Livmodersygdomme
- Kønssygdomme, kvindelige
- Stemningsforstyrrelser
- Livmoderhalssygdomme
- Puerperale lidelser
- Depressiv lidelse
- Abort, vane
- Abort, spontan
- Opførsel
- For tidlig fødsel
- Graviditetskomplikationer
- Depression, postpartum
- Obstetrisk arbejde, for tidligt
- Uterin cervikal inkompetence
- Motorisk aktivitet
- Motorisk aktivitet
- Bevægelse
- Muskuloskeletale fysiologiske fænomener
- Muskuloskeletale og neurale fysiologiske fænomener
- Terapeutik
- Øvelse
- Sengeleje
Andre undersøgelses-id-numre
- 16-0500-15
- 4308-00216B (Andet bevillings-/finansieringsnummer: Independent Research Fund Denmark)
- 1-10-72-96-25 (Anden identifikator: De Videnskabsetiske Komitéer For Region Midtjylland)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Fysisk aktivitet
-
University of ValenciaAktiv, ikke rekrutterendeAutismespektrumforstyrrelse | Attention Deficit Hyper ActivitySpanien
-
NYU Langone HealthAfsluttetAttention Deficit Hyper ActivityForenede Stater
-
Texas Woman's UniversityAfsluttetIntellektuel handicap | Autismespektrumforstyrrelse | Motoriske lidelser | Motorforsinkelse | Sanseforstyrrelser | Attention Deficit Hyper Activity
-
Cingulate TherapeuticsPremier Research Group plcAfsluttetADHD | Attention Deficit Hyperactivity Disorder | ADHD - kombineret type | Attention Deficit Hyperactivity Disorder kombineret | Attention Deficit Hyper Activity | Opmærksomhedsunderskud hyperaktivitetForenede Stater
-
Cingulate TherapeuticsSuspenderetADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder med hyperaktivitet | ADHD - kombineret type | Attention Deficit Hyperactivity Disorder kombineret | Attention Deficit Hyper Activity | Opmærksomhedsunderskud hyperaktivitetForenede Stater
-
Affiliated Hospital to Academy of Military Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking...RekrutteringAldersinterval ≥16 år, køn ubegrænset | Histopatologi bekræftet diffust stort B-celle lymfom eller højgradigt B-celle lymfom | Modtaget tidligere førstelinjekemoterapi for DLBCL eller HGBL, kunne ikke nå CR i fire cyklusser eller tilbagefald | Mindst én positiv læsion ifølge 2014 Lugano-kriterierne... og andre forholdKina
Kliniske forsøg med Activity Restriction
-
Weill Medical College of Cornell UniversityWeill Cornell Medical College in QatarTrukket tilbage
-
University of the Balearic IslandsAfsluttetBlodtryk | ModstandstræningSpanien
-
Rigshospitalet, DenmarkLundbeck Foundation; Health Care Centre Frederiksberg; The Danish Arthritis... og andre samarbejdspartnereIkke rekrutterer endnu
-
The Methodist Hospital Research InstituteRekrutteringSund og rask | Sunde frivillige | Sunde mandlige og kvindelige emnerForenede Stater
-
Hacettepe UniversityAfsluttetLivskvalitet | Demens | Ergoterapi | ÆLDRE MENNESKER | HavebrugsterapiKalkun
-
Mayo ClinicAfsluttet
-
Lauren EricksonAmerican College of Sports MedicineAfsluttetPatellofemoralt syndromForenede Stater
-
NRG OncologyPennsylvania Department of Health Commonwealth Universal Research Enhancement...AfsluttetIkke-småcellet lungekræft stadie III | Ikke-småcellet lungekræft | Tilbagevendende ikke-småcellet lungekræftForenede Stater
-
Gazi UniversityIkke rekrutterer endnu
-
University of MalayaUkendtKirurgi | Fitness Trackers | Tidlig Ambulation | Sundhedstjenester for ældreMalaysia